All In Biotech

Drug Trial Radar · NCT01410890

Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease

A Phase 3/4 Prospective Study to Characterize the Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease

Last checked: Nov 20, 2026Latest source record: Mar 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

21

Actual

Start

Nov 3, 2014

Primary completion

Nov 20, 2020

Study completion Nov 20, 2020

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Aug 5, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

* The primary objective of this study was to characterize the pharmacokinetics (PK) of alglucosidase alfa manufactured at the 4000 L scale in participants who had a confirmed diagnosis of Pompe disease. * A secondary objective of this study was to evaluate and explore the relationship between anti-recombinant human acid alpha-glucosidase antibody titers and the PK of alglucosidase alfa.

Conditions

  • Pompe Disease
  • Glycogen Storage Disease Type II (GSD II)

Interventions

  • alglucosidase alfaBiological

    Intravenous (IV) infusion of 20mg/kg body weight every other week (qow)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Alglucosidase AlfaTime frame: Pre-dose and at 1, 2, 4, 8, 12, and 24 hours Post-dose on Day 1
  2. Pharmacokinetics: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Alglucosidase AlfaTime frame: Pre-dose and at 1, 2, 4, 8, 12, and 24 hours Post-dose on Day 1
  3. Pharmacokinetics: Area Under the Plasma Concentration-Time Curve (AUC) of Alglucosidase AlfaTime frame: Pre-dose and at 1, 2, 4, 8, 12, and 24 hours Post-dose on Day 1
  4. Pharmacokinetics: Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of Alglucosidase AlfaTime frame: Pre-dose and at 1, 2, 4, 8, 12, and 24 hours Post-dose on Day 1
  5. Pharmacokinetics: Terminal Elimination Half-life (T1/2) of Alglucosidase AlfaTime frame: Pre-dose and at 1, 2, 4, 8, 12, and 24 hours Post-dose on Day 1
  6. Pharmacokinetics: Total Systemic Clearance (CL) of Alglucosidase AlfaTime frame: Pre-dose and at 1, 2, 4, 8, 12, and 24 hours Post-dose on Day 1
  7. Pharmacokinetics: Volume of Distribution at Steady State (Vss) of Alglucosidase AlfaTime frame: Pre-dose and at 1, 2, 4, 8, 12, and 24 hours Post-dose on Day 1

Locations

12 sites in 6 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 840008

    Valhalla, New York

  • Investigational Site Number 840007

    Cincinnati, Ohio

  • Investigational Site Number 840005

    Salt Lake City, Utah

  • Investigational Site Number 840003

    Fairfax, Virginia

  • Investigational Site Number 1028

    Sofia, Bulgaria

  • Investigational Site Number 356001

    New Delhi, India

  • Investigational Site Number 356002

    Vellore, India

  • Investigational Site Number 643001

    Moscow, Russia

  • Investigational Site Number 643002

    Moscow, Russia

  • Investigational Site Number 804001

    Kiev, Ukraine

  • Investigational Site Number 826003

    Birmingham, United Kingdom

  • Investigational Site Number 826002

    Salford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.